United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Home Depot

Intuit

Kohl's

Target

Tyson Foods

Walmart

The week began on a muted note, with the Dow Jones Industrial Average (DJI), the S&P 500 (SPX), and the Nasdaq Composite (IXIC) barely registering movement as traders looked ahead to a week packed with retail earnings , and this past weekend's passage of the $1.7 trillion infrastructure bill.

Dow Heads Quietly Into Holiday Season as Retail Earnings Roll In

Moderna

Republicans are disproportionately likely to say they won't get the third shot.

FDA Authorizes Booster Shots For All Adults — But 20% Of Vaccinated Americans Might Not Get One, Polls Show

Quest Diagnostics

Disney

Hertz

Southwest Airlines

MGM Resorts

With the Biden administration making the move to open U.S. land borders with Canada and Mexico, these stocks to buy can get a boost. The post 7 Stocks to Buy as America Lifts Its Travel Ban appeared first on InvestorPlace.

7 Stocks to Buy as America Lifts Its Travel Ban

BioNTech SE

FDA Gives Authorization to Two COVID-19 Boosters

Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."

FDA Authorizes Covid Boosters; New Fed Chair Soon?

Amid a  Covid-19 resurgence  in Europe, the U.S. Food and Drug Administration (FDA) today authorized Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) booster shots for all adults.

Options Bulls Blast Pfizer, Moderna Stocks on FDA Booster Approval

The FDA has authorized Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 booster shots for all U.S. adults. The agency extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older.

COVID-19 Booster Shots From Moderna, Pfizer/BioNTech Score FDA Nod All Adults

The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.

Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.

Merck

It looks to be more effective and will sell at a comparable price.

Will Pfizer's COVID Pill Crush the Hopes of Merck Investors?

The next step is for the CDC to sign off on recommendations for the booster shots.

FDA clears Pfizer and Moderna booster shots for all adults

Shares of Pfizer Inc. PFE, +1.56% rose 2.1% and of Germany-based partner BioNTech SE BNTX, +3.44% climbed 4.2% in morning trading Friday, after Health Canada authorized use of the companies' COVID-19 vaccine in children 5 to 11 years old. That's the first vaccine authorized in Canada for that age group.

Pfizer, BioNTech COVID-19 vaccine authorized in Canada for children 5 to 11 years of age

The move paves the way for millions of additional Americans to get an extra vaccine dose — but some states had opened up eligibility on their own.

FDA Authorizes Covid Booster Shots For All U.S. Adults

Moderna and Pfizer both said the FDA had expanded its emergency use authorizations for the companies' Covid-19 vaccines to allow booster doses for all adults ages 18 and above.

FDA Authorizes Pfizer and Moderna Covid-19 Vaccine Boosters for All Adults

The FDA's authorization will expand and simplify the booster-shot campaign, making all adults eligible for a third shot after six months.

The FDA just authorized booster shots of Pfizer's and Moderna's COVID-19 vaccines for all adults

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series. “As we ne

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

The stock price of Pfizer (NYSE: PFE) has seen a rise of 21% in a month following multiple positive developments, including positive data for its oral Covid-19 treatment pill, upbeat Q3 results, and more recently, closing the acquisition of Trillium Therapeutics for $2.3 billion.

Will The Rally In Pfizer Stock Continue After A Large 21% Rise In A Month?

Yes -- if the FDA focuses on protection against coronavirus infection.

Will Pfizer and BioNTech Win Authorization for Boosters for All Adults?

SPDR Gold Trust

Hotter than expected inflation represents the main risk to stocks into 20-2022. A new wave of Covid infections is also concerning and adds to uncertainties regarding the macro outlook.

It's Not Just Inflation. New Covid Surge Is A Game Changer: 2 Trades To Make Now

AstraZeneca

Bristol-Myers

GlaxoSmithKline

Eli Lilly

Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.

Look to Big Pharma for Healthy Dividends

AbbVie

Inovio Pharmaceuticals

Novavax

Sanofi

Could these top biotech stocks be worth investing in for the long term?

5 Biotech Stocks To Check Out In The Stock Market Now

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. XELJANZ is the first and only oral Janus kinase (JAK) inhibitor approved for five indications in the European Union (EU), including in adults with moderate to severe active rheumatoid arthritis (RA), adults with active psoria

Pfizer's XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis

Pfizer asked the FDA on Tuesday to authorize emergency use of the experimental pill, which has been shown to significantly cut the rate of hospitalizations and deaths

Pfizer, US gov sign $5 billion deal for possible COVID-19 treatment

The deal will secure the U.S. 10 million courses of Pfizer's experimental Covid-19 pill, providing it is approved by regulators.

U.S. Inks $5.3 Billion Deal For Pfizer's Antiviral Covid Pill — Growing Its Stockpile Of New Coronavirus Treatments

Pfizer PFE, +2.56% said Thursday it has agreed to supply the U.S. government with 10 million doses of its COVID-19 antiviral and will receive $5.29 billion assuming the treatment is authorized. Paxlovid would be the first oral antiviral of its kind.

Pfizer seeks emergency U.S. authorization for 10 million doses of new COVID-19 anti viral drug

Cardiff Oncology

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer), today announced that Pfizer Inc. (NYSE: PFE) has made a $15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. Pursuant to a securities purchase agreement between the parties, Pfizer purchased 2.4 million shares of Cardiff Oncology's common stock at a price of $6.22 per share.

News for Pfizer Stock (PFE)